Prosecution Insights
Last updated: November 15, 2026
Application No. 17/820,372

Rolling Circle Reverse Transcription of Circular RNA

Final Rejection §103§112
Filed
Aug 17, 2022
Priority
Aug 17, 2021 — provisional 63/260,323
Examiner
LIPPOLIS, ALEXANDRA ROSE
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
New England Biolabs Inc.
OA Round
2 (Final)
49%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
19 granted / 39 resolved
-11.3% vs TC avg
Strong +62% interview lift
Without
With
+61.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
62 currently pending
Career history
104
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to the amendment filed 06/22/2026, in which claims 1, 6-21, 28 and 29 were amended and claims 2 and 22-27 are cancelled. Claims 1,3-21 and 28-29 are currently pending. Applicant’s arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejection and objections not reiterated in this action have been withdrawn. This action is FINAL. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code, specifically on Page 49, Line 21. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. Specifically, Page 49 includes an embedded hyperlink. See MPEP § 608.01. Response to Amendment - Specification Although Applicant filed a marked up and clean version of the specification on 06/22/2026, the specification is still objected to for containing embedded hyperlinks. The amendment to the specification removed the “www” when it should have removed the “https://”. Respond to Amendment - Claim Objections The previous objection of claim 2 has been withdrawn in view of Applicant’s cancellation of the claim in the response filed on 06/22/2026. Response to Amendments - Claim Rejections - 35 USC § 112 The previous rejection of claim 17 under 35 U.S.C. 112(b) has been withdrawn in view of Applicant’s amendments to the claims filed on 06/22/2026. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 3-21, 28 and 29 are rejected under 35 U.S.C. 103 as being unpatentable over Armstrong et al (US 2018/0148717 A1) in view of Lambowitz et al (WO 2010/102085 A2). This is a previous rejection made in the Office Action mailed on 03/19/2026 and amended to address the amendments to the claims filed on 06/22/2026. Regarding claims 1 and 3-5, Armstrong teaches that replicating the information stored in the nucleotide sequence of a circular RNA molecule by converting the RNA molecule into a circular DNA molecule wherein generating and amplifying circular DNA molecules from their circular RNA counterparts, rare or previously unknown circular RNAs are identified [0070-71]. Armstrong teaches a method of circRNA amplification by first combining an RNA template with one or more DNA primers and a mix of dNTPs for extending the primers for creating circular DNA [0082, 0093-0094 and 0104]. Armstrong teaches that after priming, a Protoscript II reverse transcriptase is added [0093-0094 and 0104] in order to produce concatemeric first strand cDNA molecules by rolling circle reverse transcription of the circRNA [0061-0068]. Armstrong teaches rolling circle replication of the circularized first strand cDNA molecules results in long DNA strands containing tandem repeats of the cDNA sequence, thus amplifying multiple cassette copies of the original circular RNA sequence [0060]. Armstrong teaches amplification of the circular DNA copy molecules by an isothermal polymerase (φ29) and a magnetic bead DNA cleanup step [0106]. Armstrong teaches amplification of a covalently closed circular DNA template with φ29 polymerase is expected to yield high molecular weight DNA products comprised of concatemers containing tandem repeats representing the original circular GFP control RNA template [0118]. Armstrong teaches the resulting sequence data was analyzed using the bioinformatic analysis method "CIRI" which identifies signatures (specifically backsplice junctions and GT-AT splicing signals), embedded in the sequence data, specific to circular DNA molecules constructed from circular RNA molecules (identifying the consensus sequence) therefore, the samples treated with the current method exhibited greater than 10-fold more circular RNA backsplice signals demonstrating that circular DNA molecule can be constructed and amplified from endogenous circular RNA molecules contained in biological samples [0107]. Armstrong does not teach the Group II intron reverse transcriptase. Lambowitz teaches the group II intron RT assists RNA splicing by stabilizing the catalytically active RNA structure and then remains bound to the excised intron RNA in a ribonucleoprotein (RNP) that promotes intron mobility by a process termed "retrohoming” wherein retrohoming occurs by a mechanism in which the excised intron RNA in the RNPs inserts directly into a DNA target site and is reverse transcribed by the RT and during retrohoming, in which the group II intron facilitates targeting of the intron to appropriate DNA sequences, the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures: thus, group II intron RTs must have high processivity and fidelity in order to carry out their biological function [0053]. Lambowitz teaches Group II intron-derived RTs also lack RNase H activity, which can be beneficial because RNase H specifically degrades the RNA of RNA: DNA hybrids, which allows any RNA to be copied only once and can lead to reduced yields of full-length cDNA [0053]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Armstrong to include the Group II intron reverse transcriptase as taught by Lambowitz because Armstrong teaches it is within the ordinary skill in the art to use a method for identifying circRNA in a sample by combining a sample comprising circRNA with a reverse transcriptase and dNTPs in a reaction mixture for producing, by rolling circle reverse transcription of the circRNA, a reaction product comprising concatemeric first cDNA strand molecule, and characterizing the concatemeric first strand cDNA to identify the circRNA and Lambowitz teaches Group II intron-derived RTs also lack RNase H activity leading to less degradation of RNA:DNA hybrids resulting in higher full-length cDNA yields as well as the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures. One would have been motivated to make such a modification in order to receive the expected benefit of higher cDNA yields as well as more stable and compact secondary and tertiary structures of the cDNA as taught by Lambowitz. Regarding claim 6, Armstrong teaches a method of circRNA amplification by first combining an RNA template with one or more DNA primers and a mix of dNTPs for extending the primers for creating circular DNA [0082, 0093-0094 and 0104]. Regarding claims 7-10 and 12, Armstrong teaches rolling circle replication of the circularized first strand cDNA molecules which results in long DNA strands containing tandem repeats of the cDNA sequence, thus amplifying multiple cassette copies of the original circular RNA sequence [0060]. Armstrong teaches that the rolling circle cDNA replication of circular GFP RNA control wherein the first strand cDNA concatemer is 3x length of the original circRNA (~812 nt in length) with ~2400 nt in length which would comprise at least 3 complementary copies of the circRNA (Page 15, Fig. 9; [0027]). Armstrong teaches the long-read sequences of the cDNA sequencing and amplification purposes since fewer reads need to be generated for the same level of sensitivity of circular RNA detection when assaying with next-generation sequencing machines (ex. Illumin, Pacific Biosciences) [0051]. Armstrong teaches size separating the concatemeric first strand cDNA from non-concatemeric cDNA [0118-0120]. Regarding claim 11, Armstrong teaches the use of RNase R (a 3’ to 5’ RNase) and RNase H (a 5’ to 3’ RNase) for enriching the circRNA in the total RNA by degrading linear RNA [0076 and 0094]. Regarding claim 13, Armstrong does not teach wherein the sample contains circRNA and (a) does not include RNA depletion with an RNase. Lambowitz teaches Group II intron-derived RTs also lack RNase H activity, which can be beneficial because RNase H specifically degrades the RNA of RNA: DNA hybrids, which allows any RNA to be copied only once and can lead to reduced yields of full length cDNA [0053]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Armstrong to include the sample contains circRNA and does not include RNA depletion with an RNase as taught by Lambowitz because Armstrong teaches it is within the ordinary skill in the art to use a method for identifying circRNA in a sample by combining a sample comprising circRNA with a reverse transcriptase and dNTPs in a reaction mixture for producing, by rolling circle reverse transcription of the circRNA, a reaction product comprising concatemeric first cDNA strand molecule, and characterizing the concatemeric first strand cDNA to identify the circRNA and Lambowitz teaches Group II intron-derived RTs also lack RNase H activity leading to less degradation of RNA:DNA hybrids resulting in higher full-length cDNA yields as well as the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures. One would have been motivated to make such a modification in order to receive the expected benefit of higher cDNA yields as well as more stable and compact secondary and tertiary structures of the cDNA as taught by Lambowitz. Regarding claims 14 and 15, Armstrong teaches the circRNA, DNA primers and reverse transcriptase were incubated for 10 min at 25° C., followed by 50 minutes at 42° C [0104]. Regarding claims 16-18, Armstrong teaches amplification of the circular DNA copy molecules by an isothermal polymerase (φ29) and a magnetic bead DNA cleanup step [0106]. Armstrong teaches the samples treated with the current method exhibited greater than 10-fold more circular RNA backsplice signals [0107]. Regarding claim 19, Armstrong teaches in order to digest and remove single-stranded linear cDNA (leaving only cccDNA), tl1e ligation products can be treated with an exonuclease that digests linear DNA, such as Exonuclease I or T5 Exonuclease [0087]. Regarding claim 20, Armstrong teaches rolling circle replication of the circularized first strand cDNA molecules results in long DNA strands containing tandem repeats of the cDNA sequence, thus amplifying multiple cassette copies of the original circular RNA sequence [0060]. Armstrong teaches amplification of a covalently closed circular DNA template with φ29 polymerase is expected to yield high molecular weight DNA products comprised of concatemers containing tandem repeats representing the original circular GFP control RNA template [0118]. Armstrong teaches the resulting sequence data was analyzed using the bioinformatic analysis method "CIRI" which identifies signatures (specifically backsplice junctions and GT-AT splicing signals), embedded in the sequence data, specific to circular DNA molecules constructed from circular RNA molecules (identifying the consensus sequence) therefore, the samples treated with the current method exhibited greater than 10-fold more circular RNA backsplice signals demonstrating that circular DNA molecule can be constructed and amplified from endogenous circular RNA molecules contained in biological samples [0107]. Regarding claim 21, Armstrong does not teach wherein the amount of cDNA copies of the circRNA in a concatemer provides at least 2-fold higher concentration of copies of the circRNA than can be obtained using a retroviral reverse transcriptase. Lambowitz teaches unlike retroviral RTs, group II intron RTs lack an RNase H domain which can be beneficial because RNase H specifically degrades the RNA of RNA: DNA hybrids, which allows any RNA to be copied only once and can lead to reduced yields of full length cDNA [0052-0053]. Lambowitz teaches comparing the Group II intron RT (Tel4c RT) versus the MMLV RT (Superscript RT) such as, the 188-257 amplicon primer/probe set, 972,815 copies were detected with the MalE-RF-4c Tel4c RT versus 64,456 copies with Superscript RT at 6cPC (~15-fold difference) [0096]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Armstrong to include the Group II intron reverse transcriptase with a higher concentration as compared to concentration produced from retroviral reverse transcriptase as taught by Lambowitz because Armstrong teaches it is within the ordinary skill in the art to use a method for identifying circRNA in a sample by combining a sample comprising circRNA with a reverse transcriptase (Protoscript II reverse transcriptase) and dNTPs in a reaction mixture for producing, by rolling circle reverse transcription of the circRNA, a reaction product comprising concatemeric first cDNA strand molecule, and characterizing the concatemeric first strand cDNA to identify the circRNA and Lambowitz teaches Group II intron-derived RTs also lack RNase H activity leading to less degradation of RNA:DNA hybrids resulting in higher full-length cDNA yields as well as the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures. One would have been motivated to make such a modification in order to receive the expected benefit of higher cDNA yields as well as more stable and compact secondary and tertiary structures of the cDNA as taught by Lambowitz. Regarding claims 28 and 29, Armstrong teaches that replicating the information stored in the nucleotide sequence of a circular RNA molecule by converting the RNA molecule into a circular DNA molecule wherein generating and amplifying circular DNA molecules from their circular RNA counterparts, rare or previously unknown circular RNAs are identified [0070-71]. Armstrong teaches a method of circRNA amplification by first combining an RNA template with one or more DNA primers and a mix of dNTPs for extending the primers for creating circular DNA [0082, 0093-0094 and 0104]. Armstrong teaches that after priming, a Protoscript II reverse transcriptase is added [0093-0094 and 0104] in order to produce concatemeric first strand cDNA molecules by rolling circle reverse transcription of the circRNA [0061-0068]. Armstrong teaches amplification of the circular DNA copy molecules by an isothermal polymerase (φ29) and a magnetic bead DNA cleanup step [0106]. Armstrong teaches the samples treated with the current method exhibited greater than 10-fold more circular RNA backsplice signals [0107]. Armstrong does not teach the Group II intron reverse transcriptase. Lambowitz teaches the group II intron RT assists RNA splicing by stabilizing the catalytically active RNA structure and then remains bound to the excised intron RNA in a ribonucleoprotein (RNP) that promotes intron mobility by a process termed "retrohoming” wherein retrohoming occurs by a mechanism in which the excised intron RNA in the RNPs inserts directly into a DNA target site and is reverse transcribed by the RT and during retrohoming, in which the group II intron facilitates targeting of the intron to appropriate DNA sequences, the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures: thus, group II intron RTs must have high processivity and fidelity in order to carry out their biological function [0053]. Lambowitz teaches Group II intron-derived RTs also lack RNase H activity, which can be beneficial because RNase H specifically degrades the RNA of RNA:DNA hybrids, which allows any RNA to be copied only once and can lead to reduced yields of full-length cDNA [0053]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Armstrong to include the Group II intron reverse transcriptase as taught by Lambowitz because Armstrong teaches it is within the ordinary skill in the art to use a method for identifying circRNA in a sample by combining a sample comprising circRNA with a reverse transcriptase and dNTPs in a reaction mixture for producing, by rolling circle reverse transcription of the circRNA, a reaction product comprising concatemeric first cDNA strand molecule, and characterizing the concatemeric first strand cDNA to identify the circRNA and Lambowitz teaches Group II intron-derived RTs also lack RNase H activity leading to less degradation of RNA:DNA hybrids resulting in higher full-length cDNA yields as well as the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures. One would have been motivated to make such a modification in order to receive the expected benefit of higher cDNA yields as well as more stable and compact secondary and tertiary structures of the cDNA as taught by Lambowitz. Response to Arguments - Claim Rejections - 35 USC § 103 The previous rejection of claims 1-21, 28 and 29 under 35 U.S.C. 103 has been maintained in view of Applicant’s amendments and arguments filed on 06/22/2026. Applicant’s arguments have been fully considered but have not been found to be persuasive. Applicant arguments have not been found to be persuasive because Applicant argues Armstrong does not teach or suggest sequencing concatemeric first strand cDNA molecules and determining a consensus sequence from multiple repeat units contained within the concatemeric first strand cDNA molecules. Applicant continues to argue that while Armstrong generates concatemeric cDNA molecules, Armstrong does not identify any disclosure of comparing, aligning, or otherwise analyzing multiple repeat units contained within an individual concatemeric cDNA molecule to determine a consensus sequence corresponding to the circRNA. Applicant argues that Lambowitz does not remedy the deficiencies of Armstrong in teaching or suggesting the method of claim 1, nor does the combination of Armstrong and Lambowitz provide motivation to one of skill in the art to arrive at the claimed subject matter. Although not specifically identified as consensus sequences, Armstrong teaches the resulting sequence data was analyzed using the bioinformatic analysis method "CIRI" which identifies signatures (specifically backsplice junctions and GT-AT splicing signals), embedded in the sequence data, specific to circular DNA molecules constructed from circular RNA molecules therefore, the samples treated with the current method exhibited greater than 10-fold more circular RNA backsplice signals demonstrating that circular DNA molecule can be constructed and amplified from endogenous circular RNA molecules contained in biological samples [0107]. Where “CIRI”, in general terms, is the process of sequencing the concatemeric first strand cDNA molecules and determining a consensus sequence from multiple repeat units contained within the concatemeric first strand cDNA molecules, wherein the consensus sequence corresponds to the circRNA. Lambowitz is only relied on for its teachings regarding the group II intron RT assists RNA splicing by stabilizing the catalytically active RNA structure and then remains bound to the excised intron RNA in a ribonucleoprotein (RNP) that promotes intron mobility by a process termed "retrohoming” wherein retrohoming occurs by a mechanism in which the excised intron RNA in the RNPs inserts directly into a DNA target site and is reverse transcribed by the RT and during retrohoming, in which the group II intron facilitates targeting of the intron to appropriate DNA sequences, the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures: thus, group II intron RTs must have high processivity and fidelity in order to carry out their biological function [0053] including the Group II intron-derived RTs also lack RNase H activity, which can be beneficial because RNase H specifically degrades the RNA of RNA: DNA hybrids, which allows any RNA to be copied only once and can lead to reduced yields of full-length cDNA [0053]. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Armstrong to include the Group II intron reverse transcriptase as taught by Lambowitz because Armstrong teaches it is within the ordinary skill in the art to use a method for identifying circRNA in a sample by combining a sample comprising circRNA with a reverse transcriptase and dNTPs in a reaction mixture for producing, by rolling circle reverse transcription of the circRNA, a reaction product comprising concatemeric first cDNA strand molecule, and characterizing the concatemeric first strand cDNA to identify the circRNA and Lambowitz teaches Group II intron-derived RTs also lack RNase H activity leading to less degradation of RNA:DNA hybrids resulting in higher full-length cDNA yields as well as the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures. Regarding claim 28, the claim recites transcribing a circular RNA using an Intron-RT to form a population of concatemeric cDNA molecules, sequencing the concatemeric cDNA molecules, and determining a consensus sequence from multiple repeat units contained within individual concatemeric cDNAs to determine transcription fidelity of an RNA polymerase. Applicant argues Armstrong nor Lambowitz teaches or suggests determining consensus sequences from repeated units within individual concatemeric cDNAs and using those consensus sequences to evaluate transcription fidelity of an RNA polymerase as required by claim 28. As stated above, although not specifically identified as consensus sequences, Armstrong teaches the resulting sequence data was analyzed using the bioinformatic analysis method "CIRI" which identifies signatures (specifically backsplice junctions and GT-AT splicing signals), embedded in the sequence data, specific to circular DNA molecules constructed from circular RNA molecules therefore, the samples treated with the current method exhibited greater than 10-fold more circular RNA backsplice signals demonstrating that circular DNA molecule can be constructed and amplified from endogenous circular RNA molecules contained in biological samples [0107]. Where “CIRI”, in general terms, is the process of sequencing the concatemeric first strand cDNA molecules and determining a consensus sequence from multiple repeat units contained within the concatemeric first strand cDNA molecules, wherein the consensus sequence corresponds to the circRNA. Lambowitz is only relied on for its teachings regarding the group II intron RT assists RNA splicing by stabilizing the catalytically active RNA structure and then remains bound to the excised intron RNA in a ribonucleoprotein (RNP) that promotes intron mobility by a process termed "retrohoming” wherein retrohoming occurs by a mechanism in which the excised intron RNA in the RNPs inserts directly into a DNA target site and is reverse transcribed by the RT and during retrohoming, in which the group II intron facilitates targeting of the intron to appropriate DNA sequences, the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures: thus, group II intron RTs must have high processivity and fidelity in order to carry out their biological function [0053] including the Group II intron-derived RTs also lack RNase H activity, which can be beneficial because RNase H specifically degrades the RNA of RNA: DNA hybrids, which allows any RNA to be copied only once and can lead to reduced yields of full-length cDNA [0053]. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Armstrong to include the Group II intron reverse transcriptase as taught by Lambowitz because Armstrong teaches it is within the ordinary skill in the art to use a method for identifying circRNA in a sample by combining a sample comprising circRNA with a reverse transcriptase and dNTPs in a reaction mixture for producing, by rolling circle reverse transcription of the circRNA, a reaction product comprising concatemeric first cDNA strand molecule, and characterizing the concatemeric first strand cDNA to identify the circRNA and Lambowitz teaches Group II intron-derived RTs also lack RNase H activity leading to less degradation of RNA:DNA hybrids resulting in higher full-length cDNA yields as well as the group II intron RT must produce an accurate cDNA copy of the intron RNA, which is typically 2-2.5 kb long and folds into highly stable and compact secondary and tertiary structures. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEXANDRA ROSE LIPPOLIS whose telephone number is (703)756-5450. The examiner can normally be reached Monday-Friday, 8:00am to 5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JENNIFER A DUNSTON can be reached at (571) 272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALEXANDRA ROSE LIPPOLIS/Examiner, Art Unit 1637 /CELINE X QIAN/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Aug 17, 2022
Application Filed
Mar 19, 2026
Non-Final Rejection mailed — §103, §112
Jun 22, 2026
Response Filed
Sep 18, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766198
METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
4y 7m to grant Granted Oct 20, 2026
Patent 12746294
AAV DELIVERY OF NUCLEOBASE EDITORS
4y 10m to grant Granted Sep 29, 2026
Patent 12736531
METHOD FOR DETECTING VIRUS USING SSDNA FUNCTIONALIZED SENSOR
4y 4m to grant Granted Sep 15, 2026
Patent 12692500
Aptamers and use thereof
4y 11m to grant Granted Jul 28, 2026
Patent 12599637
A GENETICALLY MODIFIED LACTOBACILLUS AND USES THEREOF
4y 8m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
49%
Grant Probability
99%
With Interview (+61.7%)
Moderate
PTA Risk
Based on 39 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month